I

Isu Abxis Co Ltd
KOSDAQ:086890

Watchlist Manager
Isu Abxis Co Ltd
KOSDAQ:086890
Watchlist
Price: 4 980 KRW -1.39% Market Closed
Market Cap: 178.8B KRW
Have any thoughts about
Isu Abxis Co Ltd?
Write Note

Isu Abxis Co Ltd
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Isu Abxis Co Ltd
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
I
Isu Abxis Co Ltd
KOSDAQ:086890
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Net Issuance of Common Stock
-â‚©930.1B
CAGR 3-Years
-285%
CAGR 5-Years
-58%
CAGR 10-Years
-59%
SK Bioscience Co Ltd
KRX:302440
Net Issuance of Common Stock
â‚©397.6m
CAGR 3-Years
N/A
CAGR 5-Years
-49%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Net Issuance of Common Stock
-â‚©180.3B
CAGR 3-Years
-94%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Net Issuance of Common Stock
â‚©19B
CAGR 3-Years
-52%
CAGR 5-Years
49%
CAGR 10-Years
N/A
No Stocks Found

Isu Abxis Co Ltd
Glance View

Market Cap
177.6B KRW
Industry
Biotechnology

ISU Abxis Co., Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 143 full-time employees. The company went IPO on 2009-02-03. The firm operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.

Intrinsic Value
8 552.29 KRW
Undervaluation 42%
Intrinsic Value
Price
I

See Also

Back to Top